Skip to main content

Advertisement

SpringerLink
Log in

Quality, efficacy, safety—it is not enough!

  • Point of View
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

There is a need of comparative studies to understand the differences in term of efficacy and safety of drugs with different mechanisms of action but similar therapeutic indications. This requires changes in the European Legislation of criteria for drug approval

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Direttiva 2001/83/CE del Parlamento europeo e del Consiglio, del 6 novembre 2001, recante un codice comunitario relativo ai medicinali per uso umano

  2. Aytekin A, Ndrepepa G, Neumann F-J, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Fusaro M, Laugwitz KL, Schunkert H, Schüpke S, Kastrati A (2020) Ticagrelor or prasugrel in patients with st-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 142:2329–2337

    Article  CAS  Google Scholar 

  3. Schüpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381:1524–1534

    Article  Google Scholar 

  4. Angiolillo DJ, Patti G, Chan KT, Han Y, Huang WC, Yakovlev A, Paek D, del Aguila M, Girotra S, Sibbing D (2019) De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. J Thromb Thrombolysis 48:1–10

    Article  CAS  Google Scholar 

  5. Revol B, Jullian-Desayes I, Tamisier R, Puel V, Mallaret M, Joyeux-Faure M, Pépin JL (2018) Ticagrelor and central sleep apnea. J Am Coll Cardiol 71:2378–2379

    Article  Google Scholar 

  6. You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, Londhe A, Cho J, Park J, Schuemie M, Suchard MA, Madigan D, Hripcsak G, Gupta A, Reich CG, Ryan PB, Park RW, Krumholz HM (2020) Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA 324:1640–1650

    Article  CAS  Google Scholar 

  7. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, ten Berg J (2020) Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 395:1374–1381

    Article  CAS  Google Scholar 

  8. Choi Y, Lim H-S, Chung D et al (2018) Risk Evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res Int 2018:1574806

    PubMed  PubMed Central  Google Scholar 

  9. Zaroff JG, Cheetham TC, Palmetto N, Almers L, Quesenberry C, Schneider J, Gatto N, Corley DA (2020) Association of azithromycin use with cardiovascular mortality. JAMA Netw Open 3:e208199

    Article  Google Scholar 

  10. Fan H, Gilbert R, O’Callaghan F, Li L (2020) Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ 368:m331

    Article  Google Scholar 

  11. Pasina L, Novella A, Cortesi L, Nobili A, Tettamanti M, Ianes A (2020) Drug prescriptions in nursing home residents: an Italian multicenter observational study. Eur J Clin Pharmacol 76:1011–1019

    Article  Google Scholar 

  12. Zarowitz BJ, Tisdale JE (2019) Navigating the minefield of QTc interval-prolonging therapy in nursing facility residents. J Am Geriatr Soc 67:1508–1515

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

    Silvio Garattini

Authors
  1. Silvio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvio Garattini.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garattini, S. Quality, efficacy, safety—it is not enough!. Eur J Clin Pharmacol 77, 1425–1426 (2021). https://doi.org/10.1007/s00228-021-03110-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03110-3

Keywords

Search

Navigation